M 267
Alternative Names: anti-CD38 Fc multimer - Momenta pharmaceuticals; CD38 SIFbody - Momenta Pharmaceuticals; M267Latest Information Update: 28 Feb 2024
At a glance
- Originator Momenta Pharmaceuticals
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant proteins
- Mechanism of Action Fc receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Multiple myeloma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 01 Oct 2020 Momenta Pharmaceuticals has been acquired by Johnson & Johnson